Taking a BiTE out of toxicity: Bridging the bureaucracy gap with record speed for ALL patients

For years, a diagnosis of acute lymphoblastic leukaemia (ALL) – rare type of blood cancer and the most common childhood cancer – meant a significant degree of toxicity that extended well beyond the treatment phase. Today, science is rewriting that story.

A/Professor Shaun Fleming, Haematologist at The Alfred, and Cae Tolman, Country Senior Medical Director, explore the evolution of ALL management, the barriers still holding patients back, and the unprecedented speed at which a targeted immunotherapy is reaching those who need it most.

Until now, Blincyto (blinatumomab) – a bi-specific T-cell engager (BiTE) – was available through the PBS for patients with later stage ALL, which is often more complex to treat. Now, its expanded listing for early-stage patients marks a crucial shift. But perhaps even more remarkable is the speed at which the listing happened – a near-miraculous pace in Australia’s typically slow reimbursement process.

Yet, future advancements in blood cancers go far beyond current drug approvals. A/Professor Fleming is exploring how machine learning and AI-driven insights have the potential to personalise care, while Tolman highlighted how Amgen Australia’s local research partnerships are pushing oncology innovation to a new level.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.